{
    "nct_id": "NCT03834948",
    "official_title": "A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Previous hypersensitivity reaction to treatment with another monoclonal antibody\n2. Unresolved hypersensitivity to paclitaxel or any of its excipients (Part B only). Patients who have been desensitized may participate.\n3. Part C Only\n\n   1. History of interstitial lung disease or a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n   2. History of immune mediated colitis, hepatitis, endocrinopathies, nephritis or significant immune mediated skin reactions such as toxic epidermal necrolitis or Stevens -Johnson Syndrome\n   3. History of any autoimmune disease which required systemic therapy* in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) including but not limited to: i. Inflammatory bowel disease (including ulcerative colitis and Crohn's Disease) ii. Rheumatoid arthritis iii. Systemic progressive sclerosis (scleroderma) iv. Systemic lupus erythematosus v. Autoimmune vasculitis (e.g. Wegener's granulomatosis) *Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed)\n4. Prior treatment with a checkpoint inhibitor (anti-PD-1, PD-L1, CTLA-4 etc.) within 4 weeks prior to the start of study drug\n5. Prior treatment with a CD47-targeted therapy\n6. Prior organ or stem cell transplant",
    "miscellaneous_criteria": "Key Inclusion Criteria\n\n1. Select advanced solid tumor for which standard therapy proven to provide clinical benefit does not exist, or is no longer effective\n\n   Part A:\n   * Epithelial ovarian carcinoma (EOC)\n   * Endometrial carcinoma\n   * Castration resistant prostate cancer\n   * Non-small cell lung adenocarcinoma\n   * Papillary thyroid carcinoma\n   * Malignant mesothelioma (pleural or peritoneal)\n   * Gastroesophageal adenocarcinoma\n   * Squamous cell carcinoma of the head and neck\n\n   Part B and Part C:\n   * Platinum-resistant EOC (including fallopian tube or primary peritoneal cancer)\n   * Endometrial carcinoma\n   * Gastric adenocarcinoma/gastroesophageal adenocarcinoma\n2. Measurable disease\n3. ECOG status 0-1\n4. Resolution of prior-therapy-related adverse effects\n5. Minimum of 4 weeks or 5 half-lives since last dose of cancer therapy\n\nKey"
}